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Quality in Health Care has developed resources that assist health services
implement these important initiatives.
The introduction of these requirements have been ‘transformative’ in that it
provides the necessary stimulus for hospital executives to re-prioritise and
commit resources to the prevention of healthcare associated infections as
well as accept responsibility for governance.
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SURVEILLANCE SYSTEM OF ANTIMICROBIAL RESISTANCE AND
HEALTHCARE-ASSOCIATED INFECTIONS IN JAPAN
Satowa Suzuki, M.D., Ph.D. Chief, Laboratory of Antibiotics and Resistance,
Department of Bacteriology II. National Institute of Infectious Diseases,
Japan
Antimicrobial resistance (AMR) is of global concern, and strengthening
surveillance is critical. Japan has two major surveillance for AMR. The first
one is National Epidemiological Surveillance of Infectious Disease (NESID),
which is a national comprehensive surveillance system under infection control
act. About 110 infectious diseases including seven AMRbacterial infections are
designated as reportable disease. The second one is Japan Nosocomial Infec-
tions Surveillance（JANIS）, which has been established in 2000 as a volun-
tary-based national surveillance system targeting healthcare-associated
infections and antimicrobial resistant bacteria. It is organized by Ministry of
Health Labour andWelfare, and JANIS management office located at National
Institute of Infectious Diseases. More than 1600 hospitals are participating to
JANIS on voluntary basis as of January 1st, 2015.
JANIS consist of five divisions and Clinical Laboratory division provides
information on prevalence of AMR bacteria among clinical isolates. JANIS
collects data from hospital laboratories that have an automated system for
bacterial identification and drug susceptibility testing, and also data from
commercial laboratories to which participating hospitals are contracted.
Following conversion of those laboratory data into JANIS data format, the
data is collected to a centralized JANIS database server for analysis.
Collected data would be processed by JANIS tabulation program, which
was developed by JANIS research team, to detect data error, remove
duplicate samples and differentiate drug susceptibility pattern by an original
algorithm. JANIS has been working for years to standardize JANIS data
format and establish tabulation program. The outputs from this JANIS system
include aggregate AMR data by hospital to allow for inter-hospital compar-
ison as well as national data for AMR trends. From 2014, JANIS starts to
recruit hospitals outside Japan to participate this surveillance system.
In the presentation, a summary of JANIS annual report 2013 which is based
on data of 4.6 million samples and 3.6 million isolates submitted from 745
hospitals across Japan would be provided.SP 6-3
IMPLEMENTATION OF BUNDLE CARE TO DECREASE HEALTHCARE
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Wang-Huei Sheng a,b,*, Yee-Chun Chen a,b, I-Chen Hung a,
Ying-Ying Chang a, Yu-Ching Chang a, Mei-Chuan Hung a, Ya-Hui Huang a,
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Health care-associated infections (HAI) are associated with significant
morbidity at hospitals. We implemented active surveillance, hand hygiene
promotion, isolation cohort of resistant microorganism and bundle care since
2010. The bundle care program includes prevention care of center-line
associated bloodstream infection, urinary catheter associated urinary tract
infection, ventilator-associated pneumonia, and surgical wound infection. The
infection density decreased from5.1 per 1000 patient-days in 2011, 4.9 in 2012,
4.2 in 2013, and 3.7 in 2014, respectively. Infection density of methicillin-
resistant Staphylococcus aureus had decreased from0.18 per 1000 patient-days
in 2011 to 0.11 in 2014. Infection density of carbapenem-resistant Acineto-
bacter baumannii had had decreased from 0.15 per 1000 patient-days (&) in2011, 0.18 in 2012, 0.09 in 2013 and 0.07 in 2014 (P<0.001). A infection control
environment reduce the morbidity, mortality and medical costs. Implementa-
tion of bundle care has shown successful to decrease HAI in Taiwan.
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CLOSTRIDIUM DIFFICILE INFECTION IN WESTERN COUNTRIES: UNDER
DIAGNOSES, EPIDEMIOLOGY & EVOLVING THERAPIES
Ellie J. C. Goldstein, MD. RM Alden Research Laboratory and UCLA School of
Medicine, Los Angeles, CA, United States
C difficile associated infection (CDI) effects approximately 500-e700,000
Americans annually and is associated with significant and recently increasing
morbidity and mortality with 7,285 deaths reported in 2009. CDI also has a
substantial economic impact. The cost of treating one CDI patient in hospital
is approximately $8,000. Annual expenditures in the USA to manage CDI is
$3.2 billion/year, not including measures taken to prevent the spread of
C. difficile spores. Because of lack of suspicion and/or laboratory methodo-
logical issues it seems likely that CDI is underdiagnosed worldwide. It is esti-
mated that 40,000 cases per year are missed in European countries. Of
336,600 hospitalizations in the US, 1% of all stays develop CDI. Rates vary
for HO-HCFA CDI from rates 2.8-e9.3 per 10,000 patient days, to 1.3-e2.7
CO-HCFA and 20-e30 per 100,000 population for CA-CDI. In the USA stool cul-
ture for C. difficile is not performed and therefore epidemiological surveys
rely on data from a few centers. Between 2011-2013, 29 ribotypes types
were identified with 027 most frequent and accounting for 28.1% although
rates varied by geographic region. Ina survey of 20 European countries,
027 was the most prevalent ribotype (w18%) but varied by country for 43%
in Germany to 12% in Romania.
The therapy foe CDI has been stagnant for approximately 30 years with the
only alternatives being metronidazole or oral vancomycin. Because relapse
rates range between 20e30 %, especially in the elderly and medically
vulnerable, there has been a search for both new and more effective
therapeutic agents as well as novel preventative strategies. A recent study
(CID 2014) notes the inferiority of both metronidazole and vancomycin
compared to fidaxomicin in mild, moderate and severe CDI with statistically
superior sustained cure especially in various patient groups at greater risk of
relapse such as patients requiring concomitant antibiotics and those with
renal failure. Several new agents surotomycin, (CB-183315), SMT19969,
cadazolid and others are currently in development for CDI therapy. Other
promising alternative therapeutic approaches include monoclonal anti-
bodies, fecal biotherapy, oral spore ingestion, vaccination, and the use of
probiotics for primary prevention.SP 7-2
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While Clostridium difficile infection (CDI) has come to prominence as ma-
jor epidemics have occurred in North America and Europe over the last 15
years, awareness and surveillance of CDI in Asia have remained poor.
Limited studies performed throughout Asia indicate that CDI is also a sig-
nificant nosocomial pathogen in this region, but the true prevalence of CDI
remains unknown. A lack of regulated antibiotic use in many Asian coun-
tries suggests that the prevalence of CDI may be comparatively high. Mo-
lecular studies indicate that ribotypes 027 and 078, which have caused
significant outbreaks in other regions of the world, are rare in human
CDI in Asia, however, there have been no published investigations of pro-
duction or companion animals in the region. Variant toxin A-negative/
toxin B-positive strains of ribotype 017 caused apparent epidemics across
several Asian countries in the mid-2000s but now appear to be waning.
Ribotype smz/018 has caused widespread disease across Japan over the
last decade and more recently emerged in Korea. Both ribotype 17 and
18 have caused major outbreaks outside Asia highlighting the potential
for transfer to different countries. Better surveillance for CDI in Asia is
essential, and urgently required.
